The interassay
CV was 3.4-12.5% in the same concentration range. Dilution and recovery studies showed no significant deviation from linearity across the assay range. The assay was insensitive to interference from hemoglobin, bilirubin, and total lipids up to concentrations of 5,0.2, and 10 g/L, respectively.
No significant loss of immunological activity (analyte stability) was seen day-to-day ( 5) or after repeated freeze/thaw ( 5) cycles. We conclude that the F-PSA IRMA is an accurate, precise, and reliable tool for measuring F-PSA in human serum. PSA, prostate-specific antigen; ACT, cr,-aneichymotrypsin;
F-PSA, free PSA T-PSA, total PSA; PBS, phosphate-buffered saline; BSA, bovine serum albumin; and BPH, benign prostatic hyperplasia.
Received October 9, 1995 ; accepted April 9, 1996. management of prostate cancer. Wang et ab. [2] demonstrated that p3O (PSA) was detectableby immunoassay in several isomeric forms. Recent work has confirmed the existence of PSA in serum in two predominant molecular forms: free and cornplexed [3 -6] . The major complexed PSA form is free PSA (F-PSA) bound to a1-antichymotrypsin (PSA-ACT). Both free PSA and PSA-ACT are recognized by current commercial US Food and Drug Administration (FDA)-approved PSA tests. PSA also forms complexes with other serum-binding proteins, notably a2-macroglobubin, although the total of all non-ACTcomplexed PSA represents a smaller percentage of complexed forms of PSA [4, 5] and generally is not measurable in commercial IRMAs for PSA [5] . Differences in the relative proportions of F-PSA to PSA-ACT can affect the result obtained for total PSA (T-PSA) because of differences in the nature of the manufacturers ' calibration, the molar response of the assays, and the specificity of the antibody(ies) used [7] [8] [9] . The relative proportion of F-PSA is different in prostate cancer vs benign disease. Stenman et al. [5] found that the percentage of F-PSA was lower in patientswith untreated prostate cancer than in those with benign disease. Other studies [10, 11] revealed that concentrations of complexed PSA were higher in patientswith prostatecancer than in patientswith benign disease or in normal controls. Emphasis on the T-PSA range of 4-10 gfL has been a focalpoint for many research studies in an attempt to improve the low specificity of PSA in distinguishing benign conditions of the prostate from prostate cancer for concentrationsin thisdiagnostic"gray zone." Recently,Luderer et ab. [12] reported that quantifying T-PSA in a patient's serum in the 4-10 j.Lg/L range and calculating the proportion of F-PSA to T-PSA enhanced the ability to distinguish benign histological conditions of the prostate from prostate cancer while still retaining high sensitivity for detecting cancer. These authors reported that, within the 4-10 Mg/L T-PSA dataset,the subsetof patients whose F-PSA/T-PSA was >25% were diagnosed with benign disease only. Thirty percent of all patients with benign conditions whose T-PSA values lay between 4 and 10 .tg/L fell into this category. By increasing specificity in the diagnostic gray zone, the percentage of patients requiring biopsy to detect cancer may be reduced.
In this report we describe the analytical performance of the F-PSA immunoassay utilized by Luderer et ab. [12] .
Materials and Methods

MATERIALS
Controls and human sera. A commercially prepared ti-level tumor marker control (Lyphochek#{174},lot no. 93000; Bio-Rad, ECS Div., Anaheim, CA) was used to evaluate the precision of the T-PSA and F-PSA assays. Pooled human serum samples of various concentrations of F-PSA were used to test for analytical interference and to perform the linearity study recommended by the National Committee for Clinical Laboratory Standards (NCCLS) [13] . Individual patient's serum samples were used for the serial dilution study, precision evaluation, and stability studies. If samples were not to be assayed within 24 h, they were aliquoted in 0.5-mL volumes and frozen at -70 #{176}C.
Purified F-PSA and PSA -ACT. Purified F-PSA, prepared by the Sensabaugh-Blake technique [14] , was the gift of Thomas Stamey (Stanford University, Stanford, CA). The purified complex of PSA with a1-antichymotrypsin, PSA-ACT (Athens Research, Atlanta, GA), prepared according to the NCCLS proposed guidelines for purification [15, 16] , was >95% pure as stated in the manufacturer's specifications. Silver-stained sodium dodecyl sulfate gels of this material revealed a predominant band migrating with a molecular mass of -90 Wa and a faint trace of material migrating at a molecular mass of -30 kDa.
PROCEDURES
PSA sample fractionation.
Serum samples (0.25 mL) were fractionated on a Superdex#{174} 200 colunm (Pharmacia, Piscataway, NJ). The buffer system was 0.01 mol/L phosphate-buffered saline (PBS), pH 7.2, with 2.0 g/L bovine serum albumin (BSA). The concentrations of F-PSA and T-PSA were measured in each fraction by using the F-PSA and T-PSA assays described.
Competition immunoassay.
Specificity of the F-PSA monoclonal antibody for F-PSA was assessed by a competition immunoassay. Various amounts (0-10 000 MgIL) of purified F-PSA or PSA-ACT in a volume of 50 ML were mixed with 20 ML of '251-labebed F-PSA (10 ng). These mixtures were incubated at 37 #{176}C for 2 h with 20 ML of a 1 mg/L solution of the monocbonab antibody to F-PSA. 
of purified F-PSA in each assay. Each F-PSA mixture was run in replicates of four in two assays. Lyphochek controlswere also tested in each assay. Intraassay precision was determined by assaying four patients' serum samples and three concentrations of controls in replicates of six in one assay run. Interassay precision was determined by assaying the same four patients' serum samples and three serum controls in replicates of six over 3 days.
Linearity. Two linearity studies were performed.
To assess serial dilution linearity, we diluted with the zero calibrator three serum samples with various initial F-PSA concentrations. Four dilutions were performed for each sample. Each dilution was assayed in replicates of four in one assay run. The second linearity study was based on the NCCLS EP-6 procedure [13] . Two patients' serum samples were used to make five different pool combinations. Each pool was allowed to equilibrate overnight at 4 #{176}C and then assayed in replicates of four in one assay run.
Analytical recovery. Two concentrations (bow and medium) of a serum sample with known F-PSA concentration were added to 10 separate aliquots of assay buffer. Each serum-supplemented assay buffer and buffer control was assayed in replicates of four in one run. Because of the biological difficulties associated with the nature of endogenous PSA-binding proteins in serum, classic analytical recovery experiments utilizing serum rather than a buffer matrix could not be performed.
Stability. Two assessments of anabyte stability were performed. Day-to-day stability was demonstrated by evaluating 64 patients' serum samples assayed for F-PSA over a total of five "days," with each "day" consisting of storage for -30 mm at room temperature followed by -18 h at 4 #{176}C. For the freeze/thaw stability study, we assayed 34 patients' serum samples stored over a total of five "cycles," with each "cycle" consisting of storage for at least 1 h at -20 #{176}C followed by -30 mm at room temperature. Each sample was assayed in duplicate for each day/cycle.
Limit of detection. The detection
limit of the assay was determined by assaying the calibrator with no analyte present (zero calibrator) in replicates of 10 over 3 days. The concentration corresponding to a signal 3 SD above the mean of all replicates for the zero calibrator was used as the limit of detection for this assay. The biological detection limit was determined by the method described by Vessella et ab. [22] and Graves [23] . Briefly, five clinical serum samples with low concentrations of F-PSA (near the limit of detection for this assay) were measured in replicates of 10 over 3 days. The overall 2 SD of these measurements was determined and added to the 3 SD lowest limit of detection concentration.
Analytical interference. Hemoglobin, bilirubin, and total lipids were evaluated for possible interferences in the F-PSA assay. Hemoglobin was tested at a concentration of 5 g/L, bilirubin at 0.2 g/L, and lipids (as Intralipid#{174}; Kabi Pharmacia, Clayton, NC) at 10 g/L. Each interferent was added to 10 separate serum pools at 5% of the total sample volume. For controls, assay buffer or saline was added to 10 separate serum pools at the same 5% volume proportion.
All the sample/interference and sample/ control combinations were allowed to equilibrate overnight at 4 #{176}C before assay in replicates of four in one run.
Results
SpecfIcity. The specificity for the free and complexed PSA-ACT forms by the monocbonal antibody to F-PSA was assessed by chromatographic analysisand by competitive-bindingstudies. Fig. 1 shows the chromatographic profiles of a commercial serum control preparation (Lyphochek L3) that contained only F-PSA, and purified PSA-ACT complex after addition to a female plasma pool. The T-PSA assay detects a single peak of activity for both of these preparations, which differed only in their apparent molecular masses (-30 Wa for F-PSA and -90 Wa for the PSA-ACT complex). These molecular masses are consistent with those in other reports describing the complexed and free forms of PSA [2] [3] [4] [5] [6] . The F-PSA assay, in contrast, detects only the 30-Wa material in the serum control preparation. This demonstrates the specificity of the F-PSA assay for the free form of the antigen. The similarity of the profiles detected by the T-PSA and F-PSA immunoassays for this sample suggests that both assays detect the F-PSA form equivalently.
Competition curves measuring the ability of the monoclonal antibody to F-PSA to bind to purified F-PSA or PSA-ACT are illustrated in Fig. 2 Patients E and F had a biopsy diagnosis of prostate cancer. All biopsy diagnoses were based on pathological evaluation of sextant core samplings. The T-PSA assay detected both forms of PSA (apparent molecular masses of -90 Wa and -30 kDa). The F-PSA assay, on the other hand, detected only the 30-kDa form, demonstrating the specificity of the assay for the free form of PSA. Patients diagnosed with BPH (C and D) demonstrated by chromatography a high proportion of F-PSA. Patients diagnosed with prostate cancer had substantially lower proportions of F-PSA (E and F). This finding that the proportion of F-PSA to T-PSA is higher in patients with BPH than in patients with cancer of the prostate is consistent with the results of other investigators [5, [10] [11] [12] 26] . Antigen recovery from the chromatographs ranged from 86% to 97%, permitting comparative analysis of the peak areas.
For the comparative peak analyses, we determined the percent proportion of F-PSA by three different methods. The F-PSAJ T-PSA proportion determined by the measurements from both the F-PSA and T-PSA immunoassays before the sample was Precision. The calibration curve for the F-PSA assay is illustrated in Fig. 4 . An overall CV of 4.0% was seen for all calibrators.
We saw minimal lot-to-lot variability between different tracer preparations. Table 1 demonstrates the observed vs expected results for the Lyphochek ti-levelcontrolsand the purifiedF-PSA calibrator mixtures. The mean and ranges for the F-PSA and T-PSA determinations demonstrate that the two immunoassays are cocabibrated, i.e., determine equivalent masses of F-PSA and assess the F-PSA value in the F-PSA/T-PSA proportion equally. Table   2 demonstrates the precision of the F-PSA assay in repeated testing of both serum and control samples. For patients' serum samples, the intraassay CV range was 1.7-5.9%; the interassay CV range was 3.4-12.5%.
For the three serum controls, the intraassay CV range was 4.5-10% and the interassay CV range was 4.3-10%.
The CVs for all precision studies were <13% and demonstrated an overall mean CV of 6%. The mean ±2 SD foreach calibrator, determinedfrom fourseparateruns,is shown. Linearity. The serial dilution linearity of three serum samples is presented in Table   3 . The overall recovery for the serial dilutions ranged between 87% and 109%. The relation between concentration and dilution of the sera did not significantly deviate from linearity over the concentration range studied. For the NCCLS linearity test, the linear fit for the five sample pools was accepted (G 1.69, critical F = 2.49 at P = 0.10).
Analytical recovery. The percent recovery for the bow-concentration addition (F-PSA concentration 1.8 Mg/L) ranged between 88% and 94% (mean 91%). The percent recovery for the medium-concentration addition (F-PSA 6.1 Mg/L) ranged between 106% and 119% (mean 117%).
Stability. The day-to-day and freeze/thaw stability studies are demonstrated in Fig. 5 . In the day-to-day stability (Fig. 5A ), 97% (62 of 64) of the patients' samples tested demonstrated little shift in F-PSA concentrations after as many as 5 days at 4 #{176}C storage. The other 2 patients' samples showed a percent change in concentration of >50% from the "day 0" value. In the study of freeze/thaw stability (Fig. SB) , 91% (31 of 34) of the patients' samples tested demonstrated little shift in the F-PSA concentrations through five freeze/thaw cycles. The other 3 patients' samples showed a percent change from the "cycle 0" value of >50%. Further analysis of these five outliers from both stability studiesshowed the following:(a) Both outliersfrom study A, and two from study B were samples obtained from the same patient. Limit of detection. The analytical detection limit of the assay was determined to be 0.03 J.Lg/L F-PSA. The biological detection limit, determined from repeated testing of multiple low-concentration F-PSA serum samples, corresponding to an overall serum concentrationmean of 0.06 j.g/L (SD 0.03 tg/L), was calculated to be 0.09 pgfL.
Analytical interference. No significant interference was seen rebated to the addition of hemoglobin, bilirubin, and total lipids to all serum samples tested ( Table 4 ). The F-PSA concentration measured after the addition of the interferents ranged from 98% to 106% of the original F-PSA for hemoglobin, 88-106% for bilirubin, and 88-109% for total lipids. We saw no statistically significant differences between each supplemented group and its corresponding controls (t-test for paired means, P = 0.66, 0.33, and 0.99, respectively).
Discussion
The F-PSA double-antibody IRMA reported here is an accurate, precise, and reliable manual method for measuring F-PSA concentrations. The analytical lowest detection limit for this immunoassay was determined to be 0.03 j.g/L, and the biological detection limit was 0.09 p.gfL in human serum. The overall CVs for this assay are bow: <13% across the entire measuring range of the assay. Dilution linearity and analytical recovery were both acceptable by existing immunoassay criteria. The finding of a possible interferent effect in a few patients' samples tested during the stability studies needs further investigation. The F-PSA immunoassay method described herein yielded consistent results over 12 months of assays by four operators using numerous lots of reagents. The F-PSA results produced are sufficiently precise to be used as the numerator for calculating the F-PSAJT-PSA proportion. The FDA-approved Tosoh PA immunoassay is a robust, accurate, and precise method for measuring T-PSA. Our clinical results with this assay are consistent with that reported by many groups [17, 18] . This method yields acceptably bow CVs of <10% across the measurement range of the assay with good dilution linearity and analytical recovery characteristics.
The specificity of the F-PSA immunoassay for F-PSA was demonstrated by determination of F-PSA and PSA-ACT, both before and after separation of the components by gel-filtration chromatography and by a competitive inhibition assay. The F-PSA immunoassay detected only the second peak (-30 Wa) from the gel-filtration column, whereas the T-PSA assay accurately quantified both this peak and the first peak (-90 kDa) from the same column.
Competitive inhibition assay results comparing the ability of the monoclonal antibody to F-PSA to recognize purified F-PSA vs PSA-ACT yielded minimal crossreactivity (0.6%), further corroborating the chromatographic data.
Because the F-PSA and the T-PSA assays evaluated here possess excellent performance characteristics, the combined use of these two assays enable accurate and reliable measurement of the proportion of F-PSA to T-PSA in a human serum specimen. Although there has been much discussion about an "international standard" for T-PSA, the F-PSA method we have developed and described exclusively measures F-PSA. Accordingly, thisassayisnot relevantto the debate over the composition of an internationally acknowledged standard for T-PSA, which must measure free as well as complexed forms of PSA. The T-PSA assay we used measures F-PSA concentrations about the same as those measured by the F-PSA immunoassay.
However, the most probable use of an F-PSA result in clinical practice will be in differentiating nonmalignant vs malignant prostatic disease by determination of the proportion F-PSA/T-PSA and specificity of various T-PSA assays for the different forms of PSA have been described by others [6] [7] [8] .
Laboratories reporting results for F-PSAIT'-PSA testing must be aware that the selection and use of accurate, precise, and consistent assay methods for measuring the F-PSA as well as the T-PSA component of the F-PSA/T'-PSA proportion is crucial to providing an accurate result. Each laboratory offering F-PSA,T-PSA proportion measurements should be abbe to document the immunoselectivity, calibration, and analytical performance characteristics of each of the two assays used to calculate the proportion.
